Intensified Rituximab Induction Followed By Rituximab Maintenance For Low Grade B Cell Lymphoma: A Multicenter, Phase II Study

被引：0
|
作者：
Yamada, Kyouhei
Sawamura, Mario
Shimomura, Takeshi
Takeuchi, Makoto
Hanada, Shuichi
Komeno, Takuya
Hidaka, Michihiro
Yano, Takahiro
Kitano, Kiyoshi
Yoshida, Isao
Inoue, Nobumasa
Horibe, Keizo
Tomoyuki, Watanabe
Sunami, Kazutaka
Nagai, Hirokazu
机构：
来源：
BLOOD | 2013年 / 122卷 / 21期
关键词：
D O I：
10.1182/blood.V122.21.1797.1797
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1797
引用
收藏
页数：2
相关论文
共 50 条
  • [31] A Multicenter Phase II Study Of Bendamustine In Combination With Rituximab In Older Patients With Previously Untreated Diffuse Large B-Cell Lymphoma
    Park, Steven I.
    Richards, Kristy L.
    Asch, Adam S.
    Olajide, Oludamilola
    Deal, Allison M.
    Ivanova, Anastasia
    Wall, James G.
    Sobol, Anna L.
    Foster, Matthew C.
    Muss, Hyman B.
    Shea, Thomas C.
    BLOOD, 2013, 122 (21)
  • [32] Treatment Outcome of Steroid-Refractory Chronic Graft-Versus-Host Disease with Weekly Rituximab Followed by Maintenance Rituximab: a KSBMT Multicenter Phase II Study.
    Kim, Seok Jin
    Min, Chang Ki
    Lee, Jong Wook
    Cho, Bin
    Jung, Chu Won
    Shin, Ho Jin
    Kim, Hawk
    Jung, Joo-Sep
    Lee, Won Sik
    Yang, Deok-Hwan
    Joo, Young Don
    Kang, Hyoung Jin
    Yoon, Sung-Soo
    Kook, Hoon
    Sohn, Sang Kyun
    Min, Yoo Hong
    Park, Hee-Sook
    Kim, Hack Ki
    Ahn, Hyo Seop
    Won, Jong Ho
    BLOOD, 2009, 114 (22) : 473 - 474
  • [33] A multicenter phase II study of bendamustine, rituximab, and cytarabine (BRAC) for relapsed or refractory patients with follicular lymphoma or mantle cell lymphoma
    Nobuhiko Nakamura
    Senji Kasahara
    Junichi Kitagawa
    Hiroshi Nakamura
    Michio Sawada
    Kenji Fukuno
    Yuhei Shibata
    Yuto Kaneda
    Takeshi Hara
    Nobuhiro Kanemura
    Hisashi Tsurumi
    Masahito Shimizu
    Experimental Hematology & Oncology, 11
  • [34] A multicenter phase II study of bendamustine, rituximab, and cytarabine (BRAC) for relapsed or refractory patients with follicular lymphoma or mantle cell lymphoma
    Nakamura, Nobuhiko
    Kasahara, Senji
    Kitagawa, Junichi
    Nakamura, Hiroshi
    Sawada, Michio
    Fukuno, Kenji
    Shibata, Yuhei
    Kaneda, Yuto
    Hara, Takeshi
    Kanemura, Nobuhiro
    Tsurumi, Hisashi
    Shimizu, Masahito
    EXPERIMENTAL HEMATOLOGY & ONCOLOGY, 2022, 11 (01)
  • [35] Intensified First Cycle of Rituximab Plus Eight Cycles of Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone with Rituximab Chemotherapy for Advanced-Stage or Bulky Diffuse Large B-Cell Lymphoma: A Multicenter Phase II Consortium for Improving Survival of Lymphoma (CISL) Study
    Kim, Yu Ri
    Kim, Jin Seok
    Kim, Won Seog
    Eom, Hyeon Seok
    Yang, Deok-Hwan
    Bae, Sung Hwa
    Kim, Hyo Jung
    Lee, Jae Hoon
    Oh, Suk-Joong
    Yoon, Sung -Soo
    Kwak, Jae-Yong
    Choi, Chul Won
    Kim, Min Kyoung
    Oh, Sung Young
    Kang, Hye Jin
    Nam, Seung Hyun
    Shim, Hyeok
    Park, Joon Seong
    Mun, Yeung-Chul
    Suh, Cheolwon
    CANCER RESEARCH AND TREATMENT, 2023, 55 (04): : 1355 - 1362
  • [36] Low-grade cutaneous B-cell lymphoma:: Failure of intralesional rituximab (Mabthera®)
    Abasq, C.
    Duval-Modeste, A. -B.
    Courville, P.
    Joly, P.
    ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE, 2008, 135 (6-7): : 509 - 511
  • [37] Rituximab maintenance therapy in diffuse large B-cell lymphoma
    Trajkova, S.
    Panovska-Stavridis, I.
    Stojanovik, A.
    Dukovski, D.
    Cevreska, L.
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2012, 82 : S22 - S23
  • [38] Efficacy of Rituximab Maintenance for Diffuse Large B Cell Lymphoma with Transformation
    Uryu, Hideki
    Mishima, Yuko
    Yokoyama, Masahiro
    Nishimura, Noriko
    Kusano, Yoshiharu
    Inoue, Norihito
    Nishihara, Anna
    Fukuta, Takanori
    Shirouchi, Yuko
    Tsuyama, Naoko
    Takeuchi, Kengo
    Terui, Yasuhito
    BLOOD, 2018, 132
  • [39] Phase II study of low-grade non-Hodgkin lymphomas with fludarabine and mitoxantrone followed by rituximab consolidation: Promising results in marginal zone lymphoma
    Economopoulos, Theofanis
    Psyrri, Amanda
    Fountzilas, George
    Tsatalas, Constantinos
    Anagnostopoulos, Athanasios
    Papageorgiou, Sotirios
    Xiros, Nikolaos
    Dimopoulos, Meletios Athanasios
    LEUKEMIA & LYMPHOMA, 2008, 49 (01) : 68 - 74
  • [40] Multicenter phase II study of rituximab and temozolomide in recurrent primary central nervous system lymphoma
    Nayak, Lakshmi
    Abrey, Lauren E.
    Drappatz, Jan
    Gilbert, Mark R.
    Reardon, David A.
    Wen, Patrick Y.
    Prados, Michael
    Deangelis, Lisa M.
    Omuro, Antonio
    LEUKEMIA & LYMPHOMA, 2013, 54 (01) : 58 - 61
12345